{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T13:43:19Z","timestamp":1788615799843,"version":"build-2803163510"},"reference-count":10,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1111\/cts.70257","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T03:30:17Z","timestamp":1747798217000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["New Horizon in Clinical Development Strategy in Japan Based on New Guideline on Japanese Phase 1 Studies Prior to Multi\u2010Regional Clinical Trials"],"prefix":"10.1111","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-8680-1147","authenticated-orcid":false,"given":"Kei","family":"Fukuhara","sequence":"first","affiliation":[{"name":"Pfizer R&D Japan  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takako","family":"Shimizu","sequence":"additional","affiliation":[{"name":"OrphanPacific Inc  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5643-3522","authenticated-orcid":false,"given":"Junichi","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Biogen Japan Ltd  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2367-7300","authenticated-orcid":false,"given":"Yasuhiro","family":"Tsuda","sequence":"additional","affiliation":[{"name":"Nippon Boehringer Ingelheim Co., Ltd  Kobe Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Pharmaceuticals and Medical Devices Agency  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9884-0950","authenticated-orcid":false,"given":"Naomi","family":"Nagai","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy\/Research Institute of Pharmaceutical Sciences Musashino University  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Oikawa","sequence":"additional","affiliation":[{"name":"Kitasato Clinical Research Center Kitasato University  Sagamihara Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"Ministry of Health Labour and Welfare (MHLW) \u201cBasic Principles on Global Clinical Trials \u201d2007 https:\/\/www.pmda.go.jp\/files\/000153265.pdf."},{"key":"e_1_2_11_3_1","unstructured":"Ministry of Health Labour and Welfare (MHLW) \u201cBasic Principles on Global Clinical Trials (Reference Cases) \u201d2012 https:\/\/www.pmda.go.jp\/files\/000157520.pdf."},{"key":"e_1_2_11_4_1","unstructured":"Ministry of Health Labour and Welfare (MHLW) \u201cBasic Principles for Conducting Phase I Trials in the Japanese Population Prior to Global Clinical Trials \u201d2014 https:\/\/www.pmda.go.jp\/files\/000157777.pdf."},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2080"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s43441-024-00714-6"},{"key":"e_1_2_11_7_1","unstructured":"Ministry of Health Labour and Welfare (MHLW) \u201cBasic Principles for Conducting Phase 1 Studies in Japanese Prior to Initiating Multi\u2010Regional Clinical Trials Including Japan for Drugs in Which Early Clinical Development is Preceding Outside Japan \u201d2023 https:\/\/www.pmda.go.jp\/files\/000266773.pdf."},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2012.221"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12980"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3216"},{"key":"e_1_2_11_11_1","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA) \u201cPMDA established PMDA Washington D.C. Office as its first U.S. base \u201d2025 https:\/\/www.pmda.go.jp\/english\/int\u2010activities\/overseas\u2010office\/dc\/0001.html."}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70257","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T07:16:01Z","timestamp":1756883761000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.70257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1111\/cts.70257"],"URL":"https:\/\/doi.org\/10.1111\/cts.70257","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"2025-02-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70257"}}